ETF Holdings Breakdown of UTHR

Stock Name	United Therapeutics Corporation
Ticker	UTHR(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US91307C1027
LEI	5299005C4HZL4UWROC14

UTHR institutional holdings

The following institutional investment holdings of UTHR have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-12-09	IE00019GPKX6 (iShares MSCI ACWI UCITS ETF SGD Hedged (Acc))	14,495	USD 6,904,838	476.36
2025-12-09	IE0002W8NB38 (iShares MSCI USA Swap UCITS ETF USD (Acc))	1,280	USD 609,741	476.36
2025-12-09	IE0009QS7W62 (iShares MSCI World Health Care Sector ESG UCITS ETF USD (Acc))	931	USD 443,491 -0.7%	476.36
2025-12-09	IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc))	3,825	USD 1,822,077 -0.7%	476.36
2025-12-09	IE000D3BWBR2 (iShares S&P 500 Swap UCITS ETF USD (Dist))	13,537 200.0%	USD 6,448,485 200.7%	476.36
2025-12-09	IE000D8XC064 (iShares World Equity Enhanced Active UCITS ETF USD (Acc))	789 0.6%	USD 375,848 0.0%	476.36
2025-12-09	IE000G2LIHG9 (iShares MSCI USA ESG Screened UCITS ETF EUR Hedged (Acc))	15,028 0.1%	USD 7,158,738 -0.6%	476.36
2025-12-09	IE000KJPDY61 (iShares World Equity High Income UCITS ETF USD Inc)	361	USD 171,966	476.36
2025-12-09	IE000OHHIBC6 (iShares Core MSCI World UCITS ETF USD (Dist))	68,189	USD 32,482,512	476.36
2025-12-09	IE000WHL2ZK1 (iShares U.S. Equity High Income UCITS ETF USD Inc)	226	USD 107,657 -0.7%	476.36
2025-12-09	IE00B0M62Q58 (iShares MSCI World UCITS ETF USD (Dist))	4,562	USD 2,173,154	476.36
2025-12-09	IE00B14X4M10 (iShares MSCI North America UCITS ETF USD (Dist) USD)	922	USD 439,204 -0.7%	476.36
2025-12-09	IE00B42YS929 (iShares MSCI World GBP Hedged UCITS ETF (Acc))	241	USD 86,334 -0.5%	358.23
2025-12-09	IE00B4L5Y983 (iShares Core MSCI World UCITS ETF USD (Acc))	68,189	USD 32,482,512	476.36
2025-12-09	IE00B52SFT06 (iShares MSCI USA UCITS ETF USD (Acc))	2,270	USD 1,081,337 -0.7%	476.36
2025-12-09	IE00B8FHGS14 (iShares Edge MSCI World Minimum Volatility UCITS ETF USD (Acc))	8,914	USD 4,246,273 -0.7%	476.36
2025-12-09	IE00BD1F4K20 (iShares MSCI USA Mid-Cap Equal Weight UCITS ETF USD (Acc))	2,144	USD 1,021,316 -0.7%	476.36
2025-12-09	IE00BD1F4M44 (iShares Edge MSCI USA Value Factor UCITS ETF USD (Acc) GBP)	10,914 0.9%	USD 5,198,993 0.2%	476.36
2025-12-09	IE00BD45YS76 (iShares Core MSCI World UCITS ETF GBP Hedged (Dist))	68,189	USD 32,482,512	476.36
2025-12-09	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	33,233	USD 15,830,872	476.36
2025-12-09	IE00BFF5RX68 (iShares Edge MSCI USA Value Factor UCITS ETF USD (Dist))	10,914 0.9%	USD 5,198,993 0.2%	476.36
2025-12-09	IE00BFNM3H51 (iShares MSCI USA ESG Screened UCITS ETF USD (Dist))	15,028	USD 7,158,738	476.36
2025-12-09	IE00BFNM3J75 (iShares MSCI World ESG Screened UCITS ETF)	3,518	USD 1,675,834	476.36
2025-12-09	IE00BFNM3K80 (iShares MSCI World ESG Screened UCITS ETF USD (Dist))	3,518	USD 1,675,834 -0.7%	476.36
2025-12-09	IE00BFYTYS33 (iShares Edge MSCI World Value Factor UCITS USD Dist)	8,324	USD 3,965,221	476.36
2025-12-09	IE00BGPP8L80 (iShares Edge MSCI World Minimum Volatility UCITS ETF GBP Hedged (Acc))	8,914	USD 4,246,273 -0.7%	476.36
2025-12-09	IE00BHZPJ569 (iShares MSCI World ESG Enhanced UCITS ETF USD Acc GBP)	1,267	USD 603,548	476.36
2025-12-09	IE00BHZPJ890 (iShares MSCI USA ESG Enhanced UCITS ETF USD (Dist))	6,782	USD 3,230,674	476.36
2025-12-09	IE00BJ5JNZ06 (iShares MSCI World Health Care Sector ESG UCITS ETF)	931	USD 443,491 -0.7%	476.36
2025-12-09	IE00BKBF6H24 (iShares Core MSCI World UCITS ETF)	68,189	USD 32,482,512 -0.7%	476.36
2025-12-09	IE00BMTX1Y45 (iShares S&P 500 Swap UCITS ETF USD (Acc))	13,537	USD 6,448,485	476.36
2025-12-09	IE00BP3QZ601 (iShares Edge MSCI World Quality Factor UCITS ETF)	4,658	USD 2,218,885	476.36
2025-12-09	IE00BP3QZB59 (iShares Edge MSCI World Value Factor UCITS ETF)	8,324 0.1%	USD 3,965,221 -0.6%	476.36
2025-12-09	IE00BP3QZD73 (iShares MSCI World Mid-Cap Equal Weight UCITS ETF USD (Acc))	1,046	USD 498,273	476.36
2025-12-09	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	33,233	USD 15,830,872	476.36
2025-12-08	IE00B441G979 (iShares MSCI World EUR Hedged UCITS ETF (Acc))	2,744	USD 1,131,850 -1.8%	412.48
2025-12-08	IE00B6R52259 (iShares MSCI ACWI UCITS ETF)	14,495	USD 6,950,497 -2.0%	479.51
2025-12-08	IE00BG11HV38 (iShares MSCI World ESG Enhanced UCITS ETF USD Inc GBP)	1,267 0.2%	USD 607,539 -0.8%	479.51
2025-12-05	IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF)	392	USD 191,810 1.1%	489.31
2025-12-05	IE00BFNM3G45 (iShares MSCI USA ESG Screened UCITS ETF USD (Acc))	15,007 0.0%	USD 7,343,075 1.0%	489.31
Total =	540,327	USD 257,435,485

News associated with UTHR

Cantor Fitzgerald Increases United Therapeutics (NASDAQ:UTHR) Price Target to $525.00: United Therapeutics (NASDAQ:UTHR – Free Report) had its target price lifted by Cantor Fitzgerald from $405.00 to $525.00 in a research note published on Wednesday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biotechnology company’s stock. A number of other equities analysts also recently issued reports on the company. Jefferies Financial Group […] - 2025-09-11 04:46:17
United Therapeutics (NASDAQ:UTHR) Price Target Raised to $575.00 at Oppenheimer: United Therapeutics (NASDAQ:UTHR – Free Report) had its price objective raised by Oppenheimer from $510.00 to $575.00 in a research report released on Friday morning,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock. Several other analysts have also weighed in on the company. JPMorgan Chase & Co. cut their price […] - 2025-09-08 02:46:57
HC Wainwright Increases United Therapeutics (NASDAQ:UTHR) Price Target to $500.00: United Therapeutics (NASDAQ:UTHR – Free Report) had its target price upped by HC Wainwright from $400.00 to $500.00 in a research note published on Friday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for United Therapeutics’ FY2027 earnings at $28.37 EPS. Several other analysts […] - 2025-09-08 02:46:54
United Therapeutics Corporation (NASDAQ:UTHR) Short Interest Up 82.2% in August: United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) saw a significant increase in short interest in the month of August. As of August 15th, there was short interest totaling 2,860,000 shares, anincreaseof82.2% from the July 31st total of 1,570,000 shares. Currently,6.5% of the shares of the company are short sold. Based on an average daily […] - 2025-09-08 02:15:08
United Therapeutics (NASDAQ:UTHR) Shares Down 4.8% Following Insider Selling: United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) shares were down 4.8% during mid-day trading on Wednesday following insider selling activity. The stock traded as low as $385.50 and last traded at $385.45. Approximately 497,022 shares were traded during trading, a decline of 9% from the average daily volume of 547,000 shares. The stock had […] - 2025-09-05 02:16:54
Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 3,000 Shares of Stock: United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) Director Christopher Causey sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $423.21, for a total value of $1,269,630.00. Following the transaction, the director owned 4,865 shares in the company, valued […] - 2025-09-04 05:22:59
UTHR Crosses Above Average Analyst Target: In recent trading, shares of United Therapeutics Corp (Symbol: UTHR) have crossed above the average analyst 12-month target price of $382.58, changing hands for $404.81/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgr - 2025-09-03 08:28:18
United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 11,000 Shares: United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) EVP Paul Mahon sold 11,000 shares of the company’s stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the sale, the executive vice president directly owned 36,781 shares of the company’s […] - 2025-08-25 05:07:00
LABU, INCY, UTHR, REGN: ETF Outflow Alert: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Analysts Set United Therapeutics Corporation (NASDAQ:UTHR) PT at $379.69: United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) has earned an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among analysts […] - 2025-08-15 02:40:53
Deutsche Bank AG Cuts Stake in United Therapeutics Corporation (NASDAQ:UTHR): Deutsche Bank AG lessened its position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 6.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 134,483 shares of the biotechnology company’s stock after selling 9,146 shares during the period. Deutsche Bank AG […] - 2025-08-13 04:52:49
Notable Thursday Option Activity: TGT, UTHR, ENPH: Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Target Corp (Symbol: TGT), where a total of 35,810 contracts have traded so far, representing approximately 3.6 million underlying shares. That amounts to about 72% of T - 2025-08-07 16:22:01
977 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Purchased by Arkadios Wealth Advisors: Arkadios Wealth Advisors purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 977 shares of the biotechnology company’s stock, valued at approximately $301,000. Other hedge funds and other institutional […] - 2025-08-07 05:06:52
Mackenzie Financial Corp Sells 51 Shares of United Therapeutics Corporation (NASDAQ:UTHR): Mackenzie Financial Corp trimmed its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 1.9% during the first quarter, Holdings Channel.com reports. The institutional investor owned 2,606 shares of the biotechnology company’s stock after selling 51 shares during the quarter. Mackenzie Financial Corp’s holdings in United Therapeutics were worth $803,000 at the […] - 2025-08-06 05:07:40
Avantax Advisory Services Inc. Grows Holdings in United Therapeutics Corporation (NASDAQ:UTHR): Avantax Advisory Services Inc. grew its stake in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 226.5% during the first quarter, Holdings Channel.com reports. The fund owned 1,933 shares of the biotechnology company’s stock after acquiring an additional 1,341 shares during the period. Avantax Advisory Services Inc.’s holdings in United Therapeutics were worth $596,000 at […] - 2025-08-05 04:44:57
Allianz Asset Management GmbH Grows Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR): Allianz Asset Management GmbH lifted its holdings in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 96.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,576 shares of the biotechnology company’s stock after acquiring an additional 33,254 shares during the period. […] - 2025-07-25 08:10:49
SBI Securities Co. Ltd. Reduces Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR): SBI Securities Co. Ltd. lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 64.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 132 shares of the biotechnology company’s stock after selling 240 shares during the quarter. SBI Securities Co. Ltd.’s holdings in United Therapeutics were worth $41,000 as of […] - 2025-07-21 06:23:33
Analysts Set United Therapeutics Corporation (NASDAQ:UTHR) Target Price at $383.08: United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 […] - 2025-07-21 02:45:07
Paul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock: United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $300.31, for a total transaction of $3,303,410.00. Following the completion of the sale, the executive vice president directly owned 36,781 […] - 2025-07-16 05:40:54
United Therapeutics Corporation (NASDAQ:UTHR) Stock Position Lowered by M&T Bank Corp: M&T Bank Corp decreased its position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 28.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,464 shares of the biotechnology company’s stock after selling 965 shares during the quarter. M&T […] - 2025-07-15 06:23:31
JPMorgan Chase & Co. Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $330.00: United Therapeutics (NASDAQ:UTHR – Free Report) had its price target cut by JPMorgan Chase & Co. from $350.00 to $330.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Other equities research analysts also recently issued research reports about the stock. UBS Group […] - 2025-07-11 02:30:47
Teacher Retirement System of Texas Sells 1,343 Shares of United Therapeutics Corporation (NASDAQ:UTHR): Teacher Retirement System of Texas decreased its holdings in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 10.4% in the first quarter, HoldingsChannel.com reports. The fund owned 11,602 shares of the biotechnology company’s stock after selling 1,343 shares during the quarter. Teacher Retirement System of Texas’ holdings in United Therapeutics were worth $3,577,000 at the […] - 2025-07-09 05:13:05
Principal Financial Group Inc. Buys 309 Shares of United Therapeutics Corporation (NASDAQ:UTHR): Principal Financial Group Inc. boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 0.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,861 shares of the biotechnology company’s stock after acquiring an additional 309 shares during the quarter. Principal […] - 2025-07-08 05:41:06
United Therapeutics Corporation (NASDAQ:UTHR) Holdings Raised by Sumitomo Mitsui Trust Group Inc.: Sumitomo Mitsui Trust Group Inc. lifted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 4.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 97,727 shares of the biotechnology company’s stock after acquiring an additional 4,054 […] - 2025-07-03 05:24:58
Wealth Enhancement Advisory Services LLC Sells 2,214 Shares of United Therapeutics Corporation (NASDAQ:UTHR): Wealth Enhancement Advisory Services LLC trimmed its holdings in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 39.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,429 shares of the biotechnology company’s stock after selling 2,214 shares during the quarter. Wealth Enhancement Advisory Services […] - 2025-07-02 04:22:58
Bessemer Group Inc. Sells 6,047 Shares of United Therapeutics Corporation (NASDAQ:UTHR): Bessemer Group Inc. cut its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 67.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,866 shares of the biotechnology company’s stock after selling 6,047 shares during the quarter. Bessemer […] - 2025-07-01 06:18:52
Diversified Trust Co Purchases 1,074 Shares of United Therapeutics Corporation (NASDAQ:UTHR): Diversified Trust Co boosted its holdings in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 139.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,842 shares of the biotechnology company’s stock after purchasing an additional 1,074 shares during the quarter. Diversified Trust Co’s […] - 2025-07-01 05:30:57
Insider Selling: United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells $3,142,700.00 in Stock: United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction dated Thursday, June 26th. The stock was sold at an average price of $285.70, for a total transaction of $3,142,700.00. Following the transaction, the executive vice president now owns 36,781 shares of the […] - 2025-06-30 05:08:57
Flagship Harbor Advisors LLC Cuts Holdings in United Therapeutics Corporation (NASDAQ:UTHR): Flagship Harbor Advisors LLC reduced its holdings in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 5.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,105 shares of the biotechnology company’s stock after selling 61 shares during the quarter. Flagship Harbor Advisors […] - 2025-06-26 05:08:55
Analysts Set United Therapeutics Corporation (NASDAQ:UTHR) PT at $393.08: United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) has received an average rating of “Moderate Buy” from the thirteen brokerages that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among […] - 2025-06-26 02:40:49

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.